Evidence map›Paper›PMID 27434719›Full record

ArticlePloS one2016

Intratracheal Administration of Mesenchymal Stem Cells Modulates Tachykinin System, Suppresses Airway Remodeling and Reduces Airway Hyperresponsiveness in an Animal Model.

Konrad Urbanek, Antonella De Angelis, Giuseppe Spaziano, Elena Piegari, Maria Matteis, Donato Cappetta, Grazia Esposito, Rosa Russo, Gioia Tartaglione, Raffaele De Palma and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. New Role of Adult Lung c-kitMediators of inflammation · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Konrad UrbanekDepartment of Experimental Medicine, Section of Pharmacology, Second University of Naples, Naples, Italy.
Antonella De AngelisDepartment of Experimental Medicine, Section of Pharmacology, Second University of Naples, Naples, Italy.
Giuseppe SpazianoDepartment of Experimental Medicine, Section of Pharmacology, Second University of Naples, Naples, Italy.
Elena PiegariDepartment of Experimental Medicine, Section of Pharmacology, Second University of Naples, Naples, Italy.
Maria MatteisDepartment of Experimental Medicine, Section of Pharmacology, Second University of Naples, Naples, Italy.
Donato CappettaDepartment of Experimental Medicine, Section of Pharmacology, Second University of Naples, Naples, Italy.
Grazia EspositoDepartment of Experimental Medicine, Section of Pharmacology, Second University of Naples, Naples, Italy.
Rosa RussoDepartment of Experimental Medicine, Section of Pharmacology, Second University of Naples, Naples, Italy.
Gioia TartaglioneDepartment of Experimental Medicine, Section of Pharmacology, Second University of Naples, Naples, Italy.
Raffaele De PalmaDepartment of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy.
Francesco RossiDepartment of Experimental Medicine, Section of Pharmacology, Second University of Naples, Naples, Italy.
Bruno D'AgostinoDepartment of Experimental Medicine, Section of Pharmacology, Second University of Naples, Naples, Italy.
University of Campania "Luigi Vanvitelli" · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe need for new options for chronic lung diseases promotes the research on stem cells for lung repair. Bone marrow-derived mesenchymal stem cells (MSCs) can modulate lung inflammation, but the data on cellular processes involved in early airway remodeling and the potential involvement of neuropeptides are scarce.

objectivesTo elucidate the mechanisms by which local administration of MSCs interferes with pathophysiological features of airway hyperresponsiveness in an animal model.

methodsGFP-tagged mouse MSCs were intratracheally delivered in the ovalbumin mouse model with subsequent functional tests, the analysis of cytokine levels, neuropeptide expression and histological evaluation of MSCs fate and airway pathology. Additionally, MSCs were exposed to pro-inflammatory factors in vitro.

resultsFunctional improvement was observed after MSC administration. Although MSCs did not adopt lung cell phenotypes, cell therapy positively affected airway remodeling reducing the hyperplastic phase of the gain in bronchial smooth muscle mass, decreasing the proliferation of epithelium in which mucus metaplasia was also lowered. Decrease of interleukin-4, interleukin-5, interleukin-13 and increase of interleukin-10 in bronchoalveolar lavage was also observed. Exposed to pro-inflammatory cytokines, MSCs upregulated indoleamine 2,3-dioxygenase. Moreover, asthma-related in vivo upregulation of pro-inflammatory neurokinin 1 and neurokinin 2 receptors was counteracted by MSCs that also determined a partial restoration of VIP, a neuropeptide with anti-inflammatory properties.

conclusionIntratracheally administered MSCs positively modulate airway remodeling, reduce inflammation and improve function, demonstrating their ability to promote tissue homeostasis in the course of experimental allergic asthma. Because of a limited tissue retention, the functional impact of MSCs may be attributed to their immunomodulatory response combined with the interference of neuropeptide system activation and tissue remodeling.

Indexed as

Mesenchymal Stem Cell TransplantationAnimalsBronchoalveolar Lavage FluidGene ExpressionGenes, ReporterGreen Fluorescent ProteinsIndoleamine-Pyrrole 2,3,-DioxygenaseInterleukin-10Interleukin-13Interleukin-4Interleukin-5Intubation, IntratrachealLungMesenchymal Stem CellsMiceMice, Inbred BALB CGreen Fluorescent ProteinsIL10 protein, mouseIndoleamine-Pyrrole 2,3,-DioxygenaseInterleukin-10Interleukin-13Interleukin-4Interleukin-5OvalbuminReceptors, Neurokinin-1Receptors, Neurokinin-2

Identifiers

PMID27434719
PMCPMC4951036
OpenAlexW2489671768

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.